Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 1, 2006, Pages 29-35

  Danel, Christine ^a,d   Moh, Raoul ^a   Anzian, Amani ^a   Abo, Yao ^a   Chenal, Henri ^a   Guehi, Calixte ^a   Gabillard, Delphine ^a,b   Sorho, Souleymane ^a   Rouet, François ^a,c   Eholié, Serge ^a,c   Anglaret, Xavier ^a,b  

^a Programme PAC CI   (Côte d’Ivoire)

^b INSERM   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^d NONE   (Côte d’Ivoire)

Author keywords

Contraception; Efavirenz; HAART; Sub Saharan Africa; Tolerance; Women

Indexed keywords

AMINOTRANSFERASE; COTRIMOXAZOLE; EFAVIRENZ; ESTROGEN; HEPATITIS B SURFACE ANTIGEN; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROGESTERONE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AFRICA; ANEMIA; ANXIETY; ARTICLE; CARDIOMYOPATHY; CONTRACEPTION; CYTOLYTIC HEPATITIS; DELIRIUM; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NIGHTMARE; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SKIN MANIFESTATION; TERATOGENICITY; VERTIGO; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; CONTRACEPTION; COTE D'IVOIRE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; NERVOUS SYSTEM DISEASES; OXAZINES; PREGNANCY; PREGNANCY COMPLICATIONS; TRANSAMINASES; TREATMENT OUTCOME;

EID: 33745001919     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000219777.04927.50     Document Type: Article

References (27)

1. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision. Available at: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf. Accessed April 13, 2006.
2. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antivir Ther. 2003;8:385-393.
3. Landman R, Schiemann R, Thiam S, et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS. 2003;17:1017-1022.
4. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004;364:29-34.
5. Laurent C, Diakhaté N, Ngom Gueye N, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363-1370.
6. Jack C, Lalloo U, Karim QA, et al. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:929-934.
7. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895.
8. Danel C, Moh R, Sorho S, et al. Progress report on a structured treatment interruption (STI) trial: Trivacan ANRS 1269 trial, Abidjan, Côte d'Ivoire [Abstract WeOrB1284 2004]. Paper presented at: XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
9. Rouet F, Ekouevi D, Chaix M, et al. Real-time PCR test for human immunodeficiency virus type-1 infection in an African resource-limited setting. J Clin Microbiol. 2005;43:2709-2717.
10. Anglaret X, Messou E, Ouassa T, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS. 2003;17:575-584.
11. Anglaret X, Dakoury-Dogbo N, Bonard D, et al. Causes and empirical treatment of fever in HIV-infected adult outpatients, Abidjan, Cote d'Ivoire. AIDS. 2002;16:909-918.
12. Attia A, Huet C, Anglaret X, et al. HIV-1-related morbidity in adults, Abidjan, Cote d'Ivoire: a nidus for bacterial diseases. J Acquir Immune Defic Syndr. 2001;28:478-486.
13. WHO. Antiretroviral drugs for the treatment of HIV infection in adults and adolescents in resource-limited settings: recommendations for a public health approach (2005-2006 revisions). Presented at: Guidelines Development Group, Brief Meeting Report; June 22-23, 2005; Montreux, Switzerland. Available at: http://www.who.int/3by5/ARVmeetingreport_June2005.pdf. Accessed April 13, 2006.
14. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-1873.
15. Burnett RJ, Francois G, Kew MC, et al. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int. 2005;25:201-213.
16. Colebunders R, Izaley L, Bila K, et al. Cutaneous reactions to trimethoprim-sulfamethoxazole in African patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1987;107:599-600.
17. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials. 2002;3:279-286.
18. Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29:244-253.
19. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182-189.
20. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253-1263.
21. Law WP, Dore GJ, Duncombe CJ, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS. 2003;17:2191-2199.
22. Ekouevi D, Tonwe-Gold B, Touré H, et al. Incidence and risk factors of severe adverse events with HAART in adult patients in the MTCT Plus program in Abidjan, Côte d'Ivoire [Abstract TuPe7.3C02]. Presented at: 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil.
23. Thorne C, Newell ML. The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf. 2005;4:323-335.
24. Loko MA, Toure S, Dakoury-Dogbo N, et al. Decreasing incidence of pregnancy by decreasing CD4 cell count in HIV-infected women in Cote d'Ivoire: a 7-year cohort study. AIDS. 2005;19:443-445.
25. Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis. 2005;9:248-257.
26. Moh R, Danel C, Sorho S, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther. 2005;10:615-624.
27. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr. 2005;39:395-400.